xDRIVE for Florida-based Cancer Patients

Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially thos

Trial Details

NCT ID
NCT07167381
Phase
NA
Sponsor
First Ascent Biomedical Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • xDRIVE Tumor Profiling
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Patients with recurrent/refractory cancer patients up to age 18 (willing to sign assent if ages 7 - 17 years)
  • -OR- Patients with recurrent/refractory cancer ≥18 years of age.
  • Patients who have received at least one prior line of standard of care therapy.
  • Patients able to provide treatment and outcome information from previous line(s) of therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →